Purpose The disease course of multiple sclerosis (MS) is unpredictable, and reliable prognostic biomarkers are needed. Positron emission tomography (PET) with β-amyloid tracers is a promising tool for evaluating white matter (WM) damage and repair. Our aim was to investigate amyloid uptake in damaged (DWM) and normal-appearing WM (NAWM) of MS patients, and to evaluate possible correlations between cerebrospinal fluid (CSF) β-amyloid 1-42 (Aβ) levels, amyloid tracer uptake, and brain volumes. Methods Twelve MS patients were recruited and divided according to their disease activity into active and non-active groups. All participants underwent neurological examination, neuropsychological testing, lumbar puncture, brain magnetic resonance (MRI) imaging, and 18 F-florbetapir PET. Aβ levels were determined in CSF samples from all patients. MRI and PET images were coregistered, and mean standardized uptake values (SUV) were calculated for each patient in the NAWM and in the DWM. To calculate brain volumes, brain segmentation was performed using statistical parametric mapping software. Nonparametric statistical analyses for between-group comparisons and regression analyses were conducted. Results We found a lower SUV in DWM compared to NAWM (p < 0.001) in all patients. Decreased NAWM-SUV was observed in the active compared to non-active group (p < 0.05). Considering only active patients, NAWM volume correlated with NAWM-SUV (p = 0.01). Interestingly, CSF Aβ concentration was a predictor of both NAWM-SUV (r = 0.79; p = 0.01) and NAWM volume (r = 0.81, p = 0.01). Conclusions The correlation between CSF Aβ levels and NAWM-SUV suggests that the predictive role of β-amyloid may be linked to early myelin damage and may reflect disease activity and clinical progression.
Introduction
Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system (CNS) [1] , whose demyelination is the pathological hallmark. MS is characterized by inflammation, axonal damage, and neurodegeneration [2] . The factors that promote spontaneous remyelination or determine axonal and neuronal loss remain poorly understood [3] , and currently there are no reliable prognostic biomarkers of disease progression.
Magnetic resonance imaging (MRI) is the most widely used technique for identifying the demyelinating lesions, especially in the white matter (WM). However, no strong correlation exists between conventional MRI measures, such as T2-and T1-weighted lesion loads, and risk of disease progression, and no MRI technique is currently specific enough to assess myelin damage and repair in vivo [4] [5] [6] .
Positron emission tomography (PET) with amyloid tracers (e.g. Pittsburgh compound B, florbetapir, florbetaben, flutemetamol) was originally developed for imaging of amyloid deposition in neurodegenerative disorders and dementia [7] , but it has recently been repurposed as an imaging marker for quantification of myelin loss and repair in MS [5, [8] [9] [10] . Amyloid tracers bind extensively to WM, and its uptake decreases with demyelination [8] . The usefulness of amyloid tracers in MS is traditionally considered secondary to their nonspecific binding to WM, possibly being trapped in β-sheet structures of myelin proteins or being highly soluble in the myelin-associated lipid bilayer [10, 11] . Nevertheless, emerging evidence supports a connection between amyloid and myelin pathology. Acute WM lesions show reduced amyloid tracer uptake compared with normal-appearing WM (NAWM), reflecting more extensive myelin loss in the lesions than in the NAWM [9, 10, 12, 13] . Additionally, in patients with relapsing-remitting (RR) MS, increased uptake within the lesions was found to be associated with a more benign clinical evolution [9] . In light of these data, amyloid PET tracers may represent a new tool for monitoring MS progression and providing outcome measures [8] . Amyloid PET tracer WM uptake in MS has raised questions about its utility as a biomarker of demyelination. Moreover, amyloid precursor protein (APP) accumulates in damaged axons in MS [14, 15] , suggesting that it may constitute a reliable marker of axon demyelination. High APP immunoreactivity has been found in actively demyelinating MS lesions but not in chronic lesions, indicating a peculiar modification of APP metabolism across disease stages [16] . Moreover, β-amyloid (Aβ) may be involved in remyelination: the β-site APP-cleaving enzyme 1 (BACE1), the enzyme that processes APP to generate Aβ, is also involved in the cleavage of neuregulin 1, a protein that plays a crucial role in oligodendrocyte differentiation and remyelination. Indeed, the genetic deletion of BACE1 during development leads to hypomyelination [17] . Several studies have aimed to determine how remyelination and MS are affected by APP and the proteins expressed via APP proteolytic processing, and whether amyloid PET can provide an in vivo molecular diagnosis of this process, but the question is still open.
Reduced cerebrospinal fluid (CSF) Aβ levels have been reported in MS patients [18] [19] [20] [21] [22] and have recently been suggested as a prognostic biomarker [22, 23] .
Given these premises, the aim of the current study is twofold: (1) to assess amyloid tracer uptake in damaged WM (DWM) and NAWM of MS patients divided according to their disease activity, and (2) to investigate possible correlations between amyloid tracer uptake and CSF Aβ levels, WM brain volumes, and clinical markers of disease progression.
Materials and methods

Subjects
Twelve patients with a diagnosis of MS according to the 2010 revised McDonald criteria were recruited [24] . Seven patients had RR-MS, three patients had secondary progressive (SP) subtype, and two patients had primary progressive (PP) MS. The patients were then divided according to their disease activity in the last year before recruitment [25] : eight patients were considered active (active MS) based on clinical relapse and/or MRI findings (contrastenhancing lesions, new or unequivocally enlarging T2 lesions), whereas four patients were deemed stable, with no evidence of acute inflammation (non-active MS). The main demographic and clinical characteristics of all recruited subjects are summarized in Table 1 .
All patients underwent clinical assessment, neuropsychological evaluation, brain MRI, 18 F-florbetapir PET, and lumbar puncture (LP). LP was always performed before starting any treatment (i.e. corticosteroids). All patients underwent brain MRI for diagnostic purposes and 18 F-florbetapir PET within a maximum of 4 weeks after brain MRI. For each recruited patient, we assessed the Expanded Disability Status Scale (EDSS) score [26] and we calculated the Bayesian Risk Estimate for MS at Onset (BREMSO). The BREMSO score was created in order to assess an individual risk score calculated from demographic and clinical variables collected at disease onset: the higher the BREMSO score, the higher the risk of future disability [27] .
The neuropsychological evaluation was assessed on the same day as the 18 F-florbetapir PET using the Italian translation of the Rao Brief Repeatable Battery (BRB-N) of Neuropsychological Tests in Multiple Sclerosis [28] . Tests were administered by a trained neuropsychologist in a standardized manner, during daytime, in a quiet room, and in a fixed order. The administration of the whole battery took about 30 min. The neuropsychological battery included the following: selective reminding test (SRT), consistent long-term retrieval (SRT-CLTR), spatial recall test, oral Symbol Digit Modalities Test (SDMT), Paced Auditory Serial Addition Test at 3 (PASAT3) and 2 s (PASAT2), selective reminding test-delayed recall (SRT-D), and spatial recall test-delayed. Neuropsychological tests included in the analyses were adjusted for age, gender, and/or education, according to the Italian validation study [28] .
The current study was approved by the institutional review board of the Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico (Milan, Italy). All MS patients gave their written informed consent for this research before entering the study.
CSF collection and Aβ determination
CSF samples were collected by LP in the L3/L4 or L4/L5 interspace. Following LP, CSF samples were centrifuged at 8000 rpm for 10 min. The supernatant was aliquoted in polypropylene tubes and stored at -80°C until use. CSF cell counts, glucose, and proteins were determined. Albumin was measured by rate nephelometry. Oligoclonal bands (OCB) were evaluated by isoelectric focusing. CSF Aβ was measured using a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) kit (Fujirebio, Ghent, Belgium).
MRI acquisition
All patients underwent an MRI examination on an Achieva 3.0T scanner (Philips, Best, Netherlands). The protocol included the following: (1) a T1-weighted scan (Repetition Time (TR) 9.90 ms; Echo Time (TE) 4.61 ms; flip angle 8°; slices thickness 1 mm; gap 0), (2) fluid-attenuated inversion recovery (FLAIR) images (TR 11000 ms; TE 125 ms; flip angle 90°; slice thickness 1 mm; gap 0), and (3) a T2-weighted scan (TR 2492 ms; TE 78 ms; flip angle 90°; slice thickness 4 mm; gap 0).
PET acquisition
PET scans were obtained with a Biograph TruePoint 64 PET/ CT scanner (Siemens, Erlangen, Germany). All patients underwent 18 F-florbetapir PET scanning at rest after intravenous injection of 370 MBq. Patients were positioned comfortably in a quiet room for at least 50 min. Each acquisition included a CT transmission scan of the head (55 mAs lasting 10 s) followed by a 20-min PET list-mode acquisition. PET sections were reconstructed with four 5-min frames to verify the absence of patient movement during the acquisition, and then with one frame of all 20 min in the form of transaxial images of 168 × 168 pixels (2 mm), using the iterative 3D TrueX algorithm with eight iterations and 14 subsets, with a Gaussian filter with full width at half maximum of 4 mm, and corrected for scatter and for attenuation using density coefficients derived from the low-dose CT scan of the head obtained with the same scanner, using the proprietary software.
Neuroimaging data analysis
The statistical analyses were performed using statistical parametric mapping software (SPM12, Wellcome Centre for Human Neuroimaging, University College London, UK). Using the ImCalc function of SPM, standardized uptake value (SUV) PET maps were derived as SUV = AC/(radiotracer dose/BW), where AC represents the activity concentration in a given voxel (kBq/ml), the radiotracer dose is the injected florbetapir dose corrected for residual activity in the syringe (MBq), and BW is body weight (kg).
FLAIR images and SUV-PET images were co-registered to individual volumetric T1-weighted images.
To quantify the macroscopic WM lesion load, lesions were segmented using the lesion growth algorithm [29] as implemented in the Lesion Segmentation Tool (LST) toolbox version 2.0.15 (www.statistical-modelling.de/lst.html) for SPM. The algorithm first segments the T1 images into the main tissue classes. This information is then combined with the co-registered FLAIR intensities in order to calculate lesion belief maps. By thresholding these maps with a threshold K value of 0.2 (determined by visual inspection of the results for the patients), an initial binary lesion map is obtained, which is subsequently grown along voxels that appear hyperintense in the FLAIR image, and the region of interest (ROI) for the DWM is created. For each dataset, the WM lesion load was calculated, visually inspected to exclude the presence of macroscopic artifacts, and used for correlation analyses. Lesions in T1-weighted images were previously filled using the lesion-filling tool in the LST toolbox. The lesionfilled T1-series images were segmented according to GM, WM, and CSF tissue probability maps to generate the normalization deformation field into the Montreal Neurological Institute (MNI) space to be applied to the co-registered SUV-PET scans.
Using the WM and GM probability map of segmentation of the individual lesion-filled T1-images, we extracted the mean SUV for each patient's total WM by the co-registered SUV-PET images. To calculate the mean SUV of NAWM, the volume of interest (VOI) representing NAWM was calculated by subtracting the DWM VOI from the total WM VOI (Fig. 1) .
GM was also evaluated using the Siemens syngo ® .PET Amyloid Plaque quantification molecular imaging neurology software on the syngo.via client-server, using the cortical ROI of the anterior cingulate gyrus, orbital part of frontal lobe, superior parietal lobule, posterior cingulate gyrus, precuneus, and temporal lobe, and of the average of these six regions.
The whole cerebellum was used as the reference region for the standardized uptake value relative ratios (SUVR).
Finally, to obtain brain volumetrics, brain segmentation was performed using SPM12. For each scan, we derived the GM, total WM, NAWM, and DWM fractions, calculated as the ratio of GM, total WM, NAWM, and DWM volumes to total intracranial volume (TIV), respectively. Data were subsequently converted to percentages.
Statistical analysis
All statistical analyses were performed using SPSS 21.0 for Windows (IBM Corp., Armonk, NY, USA), GraphPad PRISM 6.0 (GraphPad Software, La Jolla, CA, USA), and SPM12.
Due to the non-normal distribution of data (as preliminarily assessed by the Shapiro-Wilk test), all between-group comparisons were tested by nonparametric inferential statistical analyses (Mann-Whitney U test and Wilcoxon test for paired t tests). We used a paired t test for the comparison of the amyloid tracer mean SUV between DWM and NAWM.
All correlation analyses were performed assessing the Pearson correlation coefficient. Linear regression analyses were performed with WM-SUV and NAWM volume as dependent variables and CSF Aβ levels as explanatory variable. Each regression model was adjusted in order to control for the potential effects of age and gender.
For all analyses, the statistical threshold was set to p < 0.05, except for correlation between NAWM-SUV and clinical assessment, which was set to p < 0.025 after Bonferroni correction for multiple comparisons (α = 0.05/2 = 0.025), and for correlation between CSF Aβ levels and clinical assessment, which was set to p < 0.016 after Bonferroni correction for multiple comparisons (α = 0.05/3 = 0.016). 
Results
The main CSF, PET, and MRI findings are summarized in Tables 2 and 3 .
Concerning the GM tracer uptake, all patients were categorized as amyloid-negative by quantitative cutoff because their GM-SUVR average was less than 1.10 [30] . No correlation was found between CSF Aβ levels and GM-SUVR average (for all SUVR see Table 3 ).
Concerning the WM tracer uptake, DWM-SUV was lower than NAWM-SUV (1.032 ± 0.112 vs. 1.128 ± 0.122; p = 0.0005; Fig. 2a ) in each subject. Comparing patients according to their clinical course (RR vs. SP/PP), no differences in NAWM-SUV or DWM-SUV were observed. Conversely, when grouping patients according to their disease activity (active vs. non-active), we found a reduced NAWM-SUV in the active group compared to the non-active group (1.077 ± 0.119 vs. 1.231 ± 0.023; p = 0.028; Fig. 2b ), whereas no significant differences in DWM-SUV were observed.
NAWM-SUV correlated with both total WM volume (r = 0.73; p = 0.006) and NAWM volume (r = 0.82; p = 0.01; Fig. 3 ), but not with DWM volume (r = −0.45; p > 0.05), in all MS patients.
Focusing on the active group, CSF Aβ levels were lower in patients with WM-SUV < 1.05 than in those with WM-SUV ≥ 1.05 (698.8 ± 32.57 vs. 1033 ± 226.4; p = 0.029; Fig. 4a ). Neither DMW-SUV nor NAWM-SUV correlated with patient age. CSF Aβ levels correlated with NAWM-SUV (r = 0.79; p = 0.017; Fig. 4b ): the lower the CSF Aβ concentration, the lower the tracer uptake in the NAWM. The linear regression analysis showed CSF Aβ levels as a predictor of NAWM-SUV (r = 0.79; p = 0.01). NAWM-SUV correlated with NAWM volume (r = 0.82; p = 0.01; Fig. 4c ), but not with DWM volume (r = −0.64; p > 0.05). The multiple regression analysis showed NAWM volume as the best predictor of NAWM-SUV (r = 0.87; p = 0.007). CSF Aβ levels correlated with NAWM volume (r = 0.81; p = 0.01; Fig. 4d ), but not with DWM volume (r = −0.36; p > 0.05). The multiple regression analysis revealed CSF Aβ levels as the best predictor of NAWM volume (r = 0.81; p = 0.007).
As regards clinical data, NAWM-SUV in active patients showed a trend towards significance in the correlation with BREMSO score (r = −0.75; p = 0.03), although the data did not remain statistically significant after Bonferroni correction.
CSF Aβ levels correlated with the PASAT2 test (r = 0.85; p = 0.007), whereas the correlations with BREMSO score (r = −0.73; p = 0.04), EDSS score (r = −0.72; p = 0.04), and PASAT3 test (r = 0.71; p = 0.04) were no longer significant after Bonferroni correction.
Discussion
In this study, we report WM-SUV data for amyloid PET in patients with active and non-active MS in order to investigate possible differences between the two groups. To the best of our knowledge, this is the first attempt to correlate CSF Aβ levels and amyloid PET in MS reported thus far.
In line with previous studies [9, 10] , we find that the amyloid tracer uptake in the largest lesion of each patient is reduced compared to their NAWM, confirming the role of amyloid PET as a biomarker of myelin loss. F-florbetapir uptake in patients with active disease is lower than that in non-active patients, suggesting an interesting link between early WM damage and disease activity. A previous study described a more marked reduction in amyloid tracer uptake in both DWM and NAWM in patients with progressive MS compared to RR-MS patients [10] . The authors speculated that such findings may be associated with the reduced remyelination present in the progressive forms of the disease [10, 31] .
We find that active patients have lower amyloid tracer uptake than non-active patients, regardless of their disease form, and that the lower uptake is not only in the DWM but also in the NAWM.
The most interesting finding of our study is that the tracer uptake in the NAWM correlates with CSF Aβ levels: the lower the uptake, the lower the CSF Aβ concentration. We hypothesize that active patients, i.e. those with lower uptake in both DWM and NAWM and with lower CSF Aβ levels, may have a reduced capacity for remyelination and consequently a higher risk of disease progression. Strengthening this hypothesis, we also find lower uptake in the NAWM and lower CSF Aβ levels in those patients with smaller NAWM volume.
We recently described a relationship between low CSF Aβ levels and worse prognosis in MS [22, 23] . In line with these findings and the hypothesis [22] , the correlation we describe between amyloid tracer uptake and CSF Aβ concentration suggests that amyloid plays a role in the progression of WM damage in MS. Thus, 18 F-florbetapir PET may represent a marker of early WM damage and a useful prognostic tool. As part of this speculation, we had already hypothesized that lower CSF Aβ levels could be associated with a decreased ability for remyelination of CNS axons, with early WM and GM damage, resulting in a higher probability of disease progression [22] . Nevertheless, the exact role played by Aβ remains to be determined. Further studies are necessary to draw a definitive picture. There are some limitations when considering our study. First, we acknowledge that this represents an exploratory study and that a larger cohort of patients will be needed to confirm our findings. The number of patients included was unfortunately limited due to the removal of the radiopharmaceutical 18 Fflorbetapir from the market in Europe in January 2018. Second, all patients underwent 18 F-florbetapir PET scanning following an acquisition protocol validated for patients with Alzheimer's disease (AD) to ensure the absence of movement during the acquisition. Our study did not aim to optimize the protocol for MS patients, but rather to apply the best protocol used to 18 Fflorbetapir PET acquisition. Because all patients, including those with active disease, were very cooperative, and none of them moved their head during the entire acquisition protocol, the 20-min static images were used for all measurements.
In conclusion, this study provides evidence of the role of amyloid PET in the assessment of MS, particularly in relation to disease activity and early prognosis. Moreover, these findings suggest a predictive role for CSF Aβ levels in MS. A replication in a larger cohort of patients is required to confirm these preliminary data. 
